IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market
IGC Pharma (NYSE American:IGC) is expanding its Holiby™ wellness brand with two new product lines: Longevity and Renew, targeting the anti-aging market. The company is implementing a multi-channel commercial strategy through e-commerce, white-label partnerships, and digital marketing.
The new products include Longevity Gummies for cognitive and cellular health support, featuring NAD+ boosting compounds, Lion's Mane Mushroom, and antioxidants, and Renew Gummies for energy and resilience, containing NAD+ metabolism support, Chaga Mushroom, and plant-based adaptogens.
This expansion complements IGC Pharma's clinical-stage drug development, including its Phase 2 trial (CALMA) of IGC-AD1 for Alzheimer's. The company is targeting the global longevity and anti-aging market, projected to exceed $182 billion by 2028, focusing on consumers aged 40+ seeking health-conscious solutions.
IGC Pharma (NYSE American:IGC) sta espandendo il suo marchio di benessere Holiby™ con due nuove linee di prodotti: Longevity e Renew, mirate al mercato anti-invecchiamento. L'azienda sta implementando una strategia commerciale multicanale attraverso l'e-commerce, partnership white-label e marketing digitale.
I nuovi prodotti includono Longevity Gummies per il supporto della salute cognitiva e cellulare, contenenti composti che potenziano il NAD+, Funghi Lion's Mane e antiossidanti, e Renew Gummies per energia e resilienza, contenenti supporto al metabolismo del NAD+, Funghi Chaga e adattogeni vegetali.
Questa espansione completa lo sviluppo di farmaci in fase clinica di IGC Pharma, inclusa la sua sperimentazione di Fase 2 (CALMA) di IGC-AD1 per l'Alzheimer. L'azienda mira al mercato globale della longevità e dell'anti-invecchiamento, previsto superare i 182 miliardi di dollari entro il 2028, concentrandosi su consumatori di età superiore ai 40 anni che cercano soluzioni orientate alla salute.
IGC Pharma (NYSE American:IGC) está expandiendo su marca de bienestar Holiby™ con dos nuevas líneas de productos: Longevity y Renew, dirigidas al mercado antienvejecimiento. La empresa está implementando una estrategia comercial multicanal a través del comercio electrónico, asociaciones de marca blanca y marketing digital.
Los nuevos productos incluyen Longevity Gummies para el apoyo de la salud cognitiva y celular, que contienen compuestos que aumentan el NAD+, hongo Lion's Mane y antioxidantes, y Renew Gummies para energía y resiliencia, que contienen soporte para el metabolismo del NAD+, hongo Chaga y adaptógenos de origen vegetal.
Esta expansión complementa el desarrollo de medicamentos en fase clínica de IGC Pharma, incluida su prueba de Fase 2 (CALMA) de IGC-AD1 para el Alzheimer. La empresa está enfocándose en el mercado global de longevidad y antienvejecimiento, que se proyecta superará los 182 mil millones de dólares para 2028, centrándose en consumidores de 40 años o más que buscan soluciones saludables.
IGC Pharma (NYSE American:IGC)는 웰니스 브랜드 Holiby™를 두 개의 새로운 제품 라인인 Longevity와 Renew로 확장하고 있으며, 이는 노화 방지 시장을 겨냥하고 있습니다. 회사는 전자 상거래, 화이트 라벨 파트너십 및 디지털 마케팅을 통해 다채널 상업 전략을 시행하고 있습니다.
새로운 제품에는 NAD+ 증가 화합물, Lion's Mane 버섯 및 항산화제가 포함된 Longevity Gummies가 있으며, 이는 인지 및 세포 건강 지원을 위한 것입니다. 또한 에너지 및 회복력 지원을 위한 Renew Gummies는 NAD+ 대사 지원, Chaga 버섯 및 식물성 적응제가 포함되어 있습니다.
이번 확장은 IGC Pharma의 임상 단계 약물 개발을 보완하며, 여기에는 알츠하이머를 위한 IGC-AD1의 2상 시험(CALMA)이 포함됩니다. 회사는 2028년까지 1,820억 달러를 초과할 것으로 예상되는 글로벌 장수 및 노화 방지 시장을 목표로 하고 있으며, 건강 지향적인 솔루션을 찾는 40세 이상의 소비자에 집중하고 있습니다.
IGC Pharma (NYSE American:IGC) étend sa marque de bien-être Holiby™ avec deux nouvelles gammes de produits : Longevity et Renew, ciblant le marché de l'anti-âge. L'entreprise met en œuvre une stratégie commerciale multicanale à travers le commerce électronique, des partenariats en marque blanche et le marketing numérique.
Les nouveaux produits comprennent des Longevity Gummies pour le soutien de la santé cognitive et cellulaire, contenant des composés stimulant le NAD+, des champignons Lion's Mane et des antioxydants, ainsi que des Renew Gummies pour l'énergie et la résilience, contenant un soutien au métabolisme du NAD+, des champignons Chaga et des adaptogènes d'origine végétale.
Cette expansion complète le développement de médicaments en phase clinique d'IGC Pharma, y compris son essai de Phase 2 (CALMA) d'IGC-AD1 pour la maladie d'Alzheimer. L'entreprise cible le marché mondial de la longévité et de l'anti-âge, qui devrait dépasser 182 milliards de dollars d'ici 2028, en se concentrant sur les consommateurs de 40 ans et plus à la recherche de solutions axées sur la santé.
IGC Pharma (NYSE American:IGC) erweitert seine Wellness-Marke Holiby™ mit zwei neuen Produktlinien: Longevity und Renew, die sich an den Anti-Aging-Markt richten. Das Unternehmen implementiert eine multikanale Handelsstrategie über E-Commerce, White-Label-Partnerschaften und digitales Marketing.
Die neuen Produkte umfassen Longevity Gummies zur Unterstützung der kognitiven und zellulären Gesundheit, die NAD+-steigende Verbindungen, Lion's Mane-Pilz und Antioxidantien enthalten, sowie Renew Gummies zur Förderung von Energie und Resilienz, die Unterstützung des NAD+-Stoffwechsels, Chaga-Pilz und pflanzliche Adaptogene enthalten.
Diese Expansion ergänzt die klinische Arzneimittelentwicklung von IGC Pharma, einschließlich der Phase-2-Studie (CALMA) von IGC-AD1 zur Behandlung von Alzheimer. Das Unternehmen zielt auf den globalen Markt für Langlebigkeit und Anti-Aging ab, der bis 2028 voraussichtlich 182 Milliarden US-Dollar übersteigen wird, und konzentriert sich auf Verbraucher ab 40 Jahren, die gesundheitsbewusste Lösungen suchen.
- Entry into high-growth anti-aging market projected at $182B by 2028
- Development of new non-dilutive revenue streams through multi-channel strategy
- Expansion of product portfolio with two new commercial products
- Synergy between nutraceutical business and pharmaceutical development
- None.
Insights
IGC Pharma's entry into the anti-aging market through Holiby represents a calculated move to generate non-dilutive revenue while leveraging their existing research infrastructure. The strategy is particularly noteworthy for a small-cap company with a market capitalization of
The product formulation strategy demonstrates market savvy by incorporating trending ingredients like Lion's Mane and Chaga mushrooms, combined with NAD+ boosters. This science-backed approach creates a distinctive value proposition in the crowded nutraceutical space. However, the challenge lies in scaling marketing and distribution efforts with resources, particularly against well-funded competitors in the
The multi-channel distribution strategy through direct-to-consumer, white-label, and private-label partnerships is strategically sound as it:
- Reduces dependency on single revenue streams
- Leverages existing manufacturing infrastructure
- Creates potential for higher margins through direct sales
- Enables rapid market testing and product iteration
The synergy between their pharmaceutical research in Alzheimer's (Phase 2 CALMA trial) and consumer products focusing on cognitive health creates a compelling narrative for both consumer trust and potential institutional partnerships. This dual-market approach could provide valuable consumer insights for their pharmaceutical development while generating near-term revenue - a important consideration for a company of this size.
- New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function -
POTOMAC, MD / ACCESS Newswire / February 20, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is expanding its Holiby™ wellness brand with the launch of two new product lines-Longevity and Renew-specifically designed to meet the increasing demand for anti-aging and cellular health solutions.
Holiby is scaling its commercial strategy through direct-to-consumer e-commerce, white-label and private-label partnerships, and targeted influencer marketing and digital advertising. This multi-channel approach positions Holiby for growth while expanding IGC Pharma's non-dilutive revenue streams.
The expansion of Holiby complements IGC Pharma's broader mission of advancing science-backed health solutions, including clinical-stage drug development for Alzheimer's and neurodegenerative diseases. The Company is currently progressing IGC-AD1, its investigational Alzheimer's therapy, through a Phase 2 clinical trial ("CALMA") while also exploring new drug candidates in metabolic and neurodegenerative disorders. The nutraceutical and pharmaceutical segments serve parallel markets, enabling IGC to leverage its research expertise, consumer insights, and distribution network to build a comprehensive health-focused portfolio.
"Longevity and Renew represent a strategic move into the high-growth anti-aging market," said Ram Mukunda, CEO of IGC Pharma. "By leveraging cutting-edge research and scalable manufacturing, we're not only delivering best-in-class products, but also unlocking new revenue opportunities for Holiby through direct sales and white-label partnerships. This expansion aligns with our vision of merging science and wellness to create long-term value for both consumers and shareholders."
The global longevity and anti-aging market is projected to exceed
The new products include:
Longevity Gummies - Cognitive & Cellular Health Support
Boosts NAD+ levels to promote healthy aging
Lion's Mane Mushroom for cognitive function and memory
Powerful antioxidants to help fight cellular damage
Renew Gummies - Energy & Resilience
Supports NAD+ metabolism for sustained vitality
Chaga Mushroom for immune defense & inflammation support
Plant-based adaptogens to enhance stress resilience
Holiby's consumer-first approach prioritizes clean-label, science-driven formulations, appealing to a growing audience of health-conscious professionals, entrepreneurs, fitness enthusiasts, and wellness advocates aged 40+. As Holiby continues to gain traction, IGC Pharma is positioned to capture market share in the booming anti-aging, longevity, and cognitive health sectors, further reinforcing the Company's commitment to innovation and strategic revenue growth.
Holiby's Longevity & Renew products are available now.
Visit us at: https://holiby.us/
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia ("CALMA") associated with Alzheimer's (clinicaltrials.gov, IGC Pharma Phase II). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 32 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions. The Company operates a wellness brand offering scientifically formulated products under the brand Holiby™ and as white-labeled formulations.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact Information
Rosalyn Christian / Walter Frank
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What new products did IGC launch in February 2024?
What is the market size potential for IGC's new anti-aging products?
What distribution channels is IGC using for its new Holiby products?
What are the key ingredients in IGC's new Longevity Gummies?
How does IGC's Holiby expansion relate to their pharmaceutical business?
